Skip to main content
PEN logo

PEN · Penumbra Inc

Track PEN — free
$320.18 +1.07 (+0.34%)
Market Cap
$12.58B
Shares
39.41M
Volume · Nov 18 81.21K Avg daily vol (3M) 356.3K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$319.11 Open$319.47 Day$319.05–320.60 52W close$278.10–359.40 Avg vol 30d373K Short int2.4M · 6.1% of shares · 5.3d Short vol65% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Jan 14, 2027 Est · unconfirmed · in 8 wks
call held Nov 5, 2025

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.

Revenue $410.15M ▲ 15.6% Net income $42.28M ▼ 7.8% Diluted EPS $1.07 ▼ 8.5%
Read from the MD&A section
Oct 29
Current report 8-K
Financial results

Penumbra Inc reported third-quarter 2026 revenue of $410.1 million, up 15.6%, global thrombectomy revenue of $279.2 million, up 18.1%, and net income of $42.3 million; pending acquisition by Boston Scientific Corporation led it to withhold full year 2026 guidance.

Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $390.05M ▲ 14.9% Net income $34.81M ▼ 23.1% Diluted EPS $0.88 ▼ 23.5%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.56B
Trailing 12 months
Net income (TTM)
$157.02M
Trailing 12 months
Revenue growth YoY
+15.6%
Year over year
Operating margin
12.1%
Trailing 12 months
P / E (TTM)
80.4
Trailing earnings · reciprocal yield 1.2%
FCF yield
1.6%
TTM · current market cap
Return on invested capital
10.6%
Trailing 12 months
Net cash
$232.88M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+14.6%
Trailing year
Short interest
6.1%
Latest settlement · 5.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Very Low
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −0%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 50%
mid-range
Momentum
relative strength
Strong
1-month return −2%
trailing
6-month return 0%
trailing
YTD return +3%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $320 › 200d $325 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +46 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.10% of shares out · ▲ +6.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
435 holders — mid 3-yr range
Squeeze score 64
elevated · 0–100
Fundamentals
Excellent
Revenue growth +17%
Y/Y
Gross margin 67%
expanding
EPS growth +1156%
Y/Y
Free cash flow $174.9M
Valuation P/E 80.4
rich
Buyback $100.0M
remaining
Balance sheet $163.8M
net cash
Quant / Vol
risk profile
Very Low
Volatility 19%
annualized · 1-yr
Max drawdown −12%
past year
ATR 0.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Jan 15, 2026
Reported revenue growth · fourth quarter 21.4% – 22%
Prior guidance period ended · from the 8-K filed Jan 15, 2026
Reported revenue growth · full year 2025 17.3% – 17.5%
Guided vs delivered · last 5 settled
Total revenue for the year (2025)
guided $1.38B – $1.38B
$1.4B Beat +1.9%
Total revenue full year 2024
guided $1.18B – $1.2B
$1.19B In line
Total company revenue full year 2023
guided $1.05B – $1.07B
$1.06B In line
Total revenue 2022
guided $840M – $845M
$847.13M Beat +0.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−0% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $320 › 200d $325 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +46 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.10% of shares out · ▲ +6.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
435 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $278 Now $319 · 50% Range high $359
vs 200-day avg -2% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PEN
Penumbra Inc
this stock
$12.58B +2.6% +17.5% 80.4 6.1%
ABT
Abbott Laboratories
$181.35B -16.4% +5.7% 39.1 1.1%
MDT
Medtronic plc
$130.88B +6.5% +8.4% 25.2 1.8%
SYK
Stryker Corp
$120.88B -9.7% +11.2% 33.8 1.7%
BSX
Boston Scientific Corp
$62.37B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
435
% held
88.7%
Net QoQ
+821.6K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
343
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
5.3d
Change
+140.6K sh
View
Short Volume
Short vol %
65%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
9.2K
Value
$3.0M
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
35.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Jul 10, 2025
View
Financials
Financials
Revenue (FY)
$1.4B
Net income (FY)
$177.7M
EPS diluted
$4.52
View
Buybacks
Authorized
$200.0M
Remaining
$100.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
15

Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.

View
Proposed Sales
Value
$32.8K
Shares
100
Filed
Apr 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Penumbra, Inc. Reports Third Quar…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
PEN -0.7% -1.6% +0.1% +0.1% +2.6%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +1.6% +3.2% +3.0% +3.1% -4.8%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$200.00M
Spent (derived)
$100.00M
Remaining
$100.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1321732 CUSIP 70975L107 13F (30d) 445 filings 414 filers Visit website Investor relations